Matthew Hershenhorn's questions to Axsome Therapeutics Inc (AXSM) leadership • Q2 2025
Question
Matthew Hershenhorn asked how Axsome plans to leverage its Sunosi commercial team for the AXS-12 launch and about its overall strategy in narcolepsy with two products.
Answer
Chief Commercial Officer Ari Maizel highlighted the 'near perfect overlap' in physician targets, allowing the Sunosi team to be fully leveraged for AXS-12, creating a 'real synergistic opportunity.' He noted that polypharmacy is common, and with distinct indications, he could foresee combination use of the two products.